June 2026
Microdosing
What June 2026's 6 new studies found, synthesized from the papers below. All Microdosing research →
The synthesis
Synthesized from 6 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Microdosing, micro-dosing, sub-perceptual dosing, low-dose psychedelics, then ranked by relevance.
Research on microdosing published in June 2026 indicates that the evidence for its benefits remains weak and inconsistent. Preclinical work in rats found no behavioral or neurogenic effects from chronic psilocin microdosing, while an umbrella review of human studies found only a small decrease in cognitive control and no significant mood improvements. Observational surveys show that microdosing is relatively common among psychedelic users and is associated with mental health symptoms and adverse childhood events, but these correlational findings do not demonstrate efficacy.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats. 2026 | preclinical animal study | No effect | Chronic psilocin microdosing did not affect locomotor activity, depressive-like behavior, sociability, novelty seeking, or dentate gyrus cell proliferation. | |
| Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis 2026 | umbrella review with narrative synthesis | 1614 | Mixed | The only significant pooled effect was a small decrease in cognitive control; all other mood and cognitive domains were non-significant. |
| Psychedelic Use, Microdosing, Motives, and Information and Product Sources Among Young Adults in the United States 2026 | observational survey | 1614 | Unclear | Among lifetime psychedelic users, 26.5% had ever microdosed; microdosing was associated with more anxiety symptoms and adverse childhood events. |
| Beyond Psychedelic Microdosing: Therapeutic Potential, Neuropharmacology, and Safety Considerations in Low-Dose Psychoactive Use 2026 | review | Unclear | The review argues that microdosing is not a single phenomenon and that substance class, dose-response, and evidence strength must be separated to evaluate therapeutic potential. | |
| Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series 2026 | case series | 3 | Supports | Three participants showed clinical improvement following an integrative iboga microdosing protocol paired with psychotherapy. |
| U.S. Psychedelic Use and Microdosing in 2025: Insights from a Probability-Based and Nationally Representative Survey. 2026 | observational survey | Unclear | The survey provides prevalence data on psychedelic use and microdosing for psilocybin, LSD, and MDMA in the U.S. in 2025. |
Chronic psilocin microdosing did not affect locomotor activity, depressive-like behavior, sociability, novelty seeking, or dentate gyrus cell proliferation.
preclinical animal study
The only significant pooled effect was a small decrease in cognitive control; all other mood and cognitive domains were non-significant.
umbrella review with narrative synthesis Sample size: 1614
Among lifetime psychedelic users, 26.5% had ever microdosed; microdosing was associated with more anxiety symptoms and adverse childhood events.
observational survey Sample size: 1614
The review argues that microdosing is not a single phenomenon and that substance class, dose-response, and evidence strength must be separated to evaluate therapeutic potential.
review
Three participants showed clinical improvement following an integrative iboga microdosing protocol paired with psychotherapy.
case series Sample size: 3
The survey provides prevalence data on psychedelic use and microdosing for psilocybin, LSD, and MDMA in the U.S. in 2025.
observational survey
Points of agreement
- Preclinical and umbrella review evidence converge on the absence of robust positive effects of microdosing on mood and cognition.
- Observational surveys converge on the finding that microdosing is a common practice among psychedelic users and is associated with mental health symptoms and adverse childhood experiences.
Conflicts
- The preclinical rat study found no behavioral effects, while the iboga case series reported clinical improvement; however, these involve different substances and populations.
- The umbrella review found a small negative effect on cognitive control, whereas some narrative reviews and surveys suggest potential benefits, though not statistically significant.
Gaps
- No large, well-controlled RCTs of microdosing in humans were included; the umbrella review highlights high overlap and expectancy bias.
- Durability of any effects is unstudied; the preclinical study assessed behavior 48h post-dose, but long-term outcomes are unknown.
- Diverse substances (psilocin, iboga, LSD, psilocybin) and doses are conflated; the review (id 27248) argues that substance-specific evidence is needed.
- Blinding and placebo control are lacking in most human studies; expectancy effects are a major confound.